Get the Stockscreener App
2.63
6.05%
0.15
After Hours:
2.67
0.04
+1.52%
Humacyte Inc stock is traded at $2.63, with a volume of 4.54M.
It is up +6.05% in the last 24 hours and up +80.14% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$2.48
Open:
$2.48
24h Volume:
4.54M
Relative Volume:
1.04
Market Cap:
$407.97M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-2.4579
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
+12.39%
1M Performance:
+80.14%
6M Performance:
-40.23%
1Y Performance:
-64.89%
1-Day Range:
$2.414
$2.72
1-Week Range:
$2.17
$2.72
52-Week Range:
$1.15
$9.97
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
2.63 | 362.98M | 0 | -110.78M | -75.59M | -1.07 |
|
ONC
Beigene Ltd Adr
|
240.41 | 25.57B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.10 | 111.79B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 39.90M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.85 | 65.28B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.93 | 6.31B | 0 | -153.72M | -103.81M | -2.00 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet - MSN
Is Humacyte (NASDAQ:HUMA) A Risky Investment? - simplywall.st
Humacyte at H.C. Wainwright Conference: Promising Developments in SimVess By Investing.com - Investing.com Nigeria
Humacyte at H.C. Wainwright Conference: Promising Developments in SimVess - Investing.com Australia
Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq - The Manila Times
Humacyte CEO Reveals Latest Bioengineered Tissue Developments at Elite Nasdaq Conference - Stock Titan
Humacyte’s Earnings Call Highlights Success and Challenges - TipRanks
Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates - MSN
Humacyte (HUMA) Receives Buy Rating and $4.00 Price Target from HC Wainwright & Co. | HUMA Stock News - GuruFocus
Humacyte (HUMA) Gains Buy Rating with $4 Target | HUMA Stock New - GuruFocus
Benchmark cuts Humacyte stock target to $14, maintains Buy rating By Investing.com - Investing.com South Africa
Humacyte (HUMA) Reports Lower-Than-Expected Q1 Revenue Amid Symv - GuruFocus
Humacyte, Inc.: Spare Parts for People - Outsider Club
Humacyte outlines expansion of Symvess to 45 hospitals while targeting BLA submission for ATEV in dialysis by 2026 - MSN
Humacyte (HUMA) Gains Buy Rating with $4 Target | HUMA Stock News - GuruFocus
Benchmark cuts Humacyte stock target to $14, maintains Buy rating - Investing.com
Humacyte (HUMA) Price Target Reduced by Benchmark Amid Positive Outlook | HUMA Stock News - GuruFocus
Humacyte (HUMA) Focuses on Symvess Launch and Expansion Plans - GuruFocus
Humacyte, Inc. (NASDAQ:HUMA) Q1 2025 Earnings Call Transcript - Insider Monkey
Humacyte price target lowered to $14 from $17 at Benchmark - TipRanks
Durham firm with battered stock cuts jobs to save cash - The Business Journals
Humacyte Reports Q1 2025 Earnings and Strategic Progress - TipRanks
Earnings call transcript: Humacyte Q1 2025 beats EPS forecast, stock surges - Investing.com Nigeria
Humacyte, Inc. SEC 10-Q Report - TradingView
Positive Momentum and Financial Stability Drive Buy Recommendation for Humacyte - TipRanks
Humacyte (HUMA) Receives Continued 'Buy' Rating from Analyst | - GuruFocus
Transcript : Humacyte, Inc., Q1 2025 Earnings Call, May 13, 2025 - marketscreener.com
Humacyte (HUMA) Anticipates Q1 Earnings Announcement - GuruFocus
Humacyte, Inc. Reports First Quarter 2025 Financial Results and Market Launch of Symvess™ for Vascular Trauma Treatment - Nasdaq
Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update - TradingView
Humacyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Humacyte Q1 2025 Earnings Call Transcript - MarketBeat
Levi & Korsinsky Notifies Shareholders of Humacyte, Inc. (HUMA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Shareholders - ACCESS Newswire
HUMA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
HUMA Shareholders Have Opportunity to Lead Humacyte, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Class Action Filed Against Humacyte, Inc. (HUMA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. LawsuitHUMA - ACCESS Newswire
HUMA LAWSUIT ALERT: Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Investors in Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - ACCESS Newswire
Humacyte, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More InformationHUMA - ACCESS Newswire
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc.(HUMA) Shareholders - ACCESS Newswire
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025 - The Manila Times
Humacyte, Inc. to Release First Quarter 2025 Financial Results on May 13, 2025 - Nasdaq
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA ViolationsHagens Berman - ACCESS Newswire
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.70%
1.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):